Chattem, Inc., in September 2008, resolved all Dexatrim cases pending against it for US$13,250,000 of which US$2,545,000 was funded from the proceeds of the Dexatrim settlement trust.
The Company is not currently aware of any additional product liability claims relating to…
Chattem, Inc., as of Jan. 22, 2009, faced about 174 lawsuits related to its Icy Hot Heat Therapy products.
Of the 174 cases, about 170 consumers had pending claims against the Company along with four products liability lawsuits alleging burns and…
Chattem, Inc., for the current annual policy period beginning Sept. 1, 2008, maintains product liability insurance coverage in the amount of US$30 million through its captive insurance subsidiary, of which about US$2,803,000 has been funded as of Jan. 22, 2009.
The…
Chattem Inc., during the quarterly period ended Aug. 31, 2008, resolved for US$13.25 million all 26 individual claims alleging the development of pulmonary arterial hypertension as a result of ingesting Dexatrim containing ephedrine.
On Dec. 30, 2003, the U.S. Food…
Complaints against Chattem, Inc. relating to ingestion of products containing phenylpropanolamine (PPA) remain pending.
The Company was named as a defendant in a number of lawsuits alleging that the plaintiffs were injured as a result of ingestion of products containing…
Chattem, Inc. maintains product liability insurance coverage in the amount of US$30 million through its captive insurance subsidiary for the current annual policy period beginning Sept. 1, 2008.
The Company maintains insurance coverage for product liability claims relating to its products…
Chattem, Inc. reports that as of Oct. 2, 2008, there were 132 consumers with pending claims and three product liability lawsuits have been filed against the Company alleging burns and skin irritation from the use of its Icy Hot Heat…